Grace Therapeutics

Grace Therapeutics

Pharmaceuticals, 2 Tower CTR BLVD, East Brunswick, New Jersey, 08816, United States, 1-10 Employees

gtrx.com

  • facebook
  • LinkedIn

phone no Phone Number: +16*********

Who is GRACE THERAPEUTICS

Grace Therapeutics is an innovative specialty pharmaceutical company with a focus on rare and orphan disease. Grace's strategy is to develop novel delivery technologies that dramatically ...

Read More

map
  • 2 Tower CTR BLVD, East Brunswick , New Jersey, 08816, United States Headquarters: 2 Tower CTR BLVD, East Brunswick , New Jersey, 08816, United States
  • 2014 Date Founded: 2014
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 8049

checked-icon Does something look wrong? Fix it. | View contact records from GRACE THERAPEUTICS

Grace Therapeutics Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Grace Therapeutics

Answer: Grace Therapeutics's headquarters are located at 2 Tower CTR BLVD, East Brunswick, New Jersey, 08816, United States

Answer: Grace Therapeutics's phone number is +16*********

Answer: Grace Therapeutics's official website is https://gtrx.com

Answer: Grace Therapeutics's revenue is $1 Million to $5 Million

Answer: Grace Therapeutics's SIC: 8049

Answer: Grace Therapeutics has 1-10 employees

Answer: Grace Therapeutics is in Pharmaceuticals

Answer: Grace Therapeutics contact info: Phone number: +16********* Website: https://gtrx.com

Answer: Grace Therapeutics is an innovative specialty pharmaceutical company with a focus on rare and orphan disease. Grace's strategy is to develop novel delivery technologies that dramatically improve the clinical outcomes of drugs previously approved for use in humans. Our selective pipeline screening model supports the development of differentiated products with a unique evidence-based and outcomes-driven value proposition . Our pipeline consists of three distinct assets all in late stage clinical development for the treatment of Postherpetic Neuralgia, Subarachnoid Hemorrhage, and Ataxia Telangiectasia. We intend to pursue multiple commercialization options for these products including their proprietary platform technologies for maximum value creation. Our team comprises accomplished drug delivery scientists and commercial executives with a proven track record of bench-to-bedside success.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access